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ABSTRACT
Objective To study the relation between low walking
speed and the risk of death in older people, both overall
and with regard to the main causes of death.
Design Prospective cohort study.
Setting Dijon centre (France) of the Three-City study.
Participants 3208 men and women aged ≥65 living in the
community,recruitedfrom1999to2001,andfollowedfor
an average of 5.1 years.
Main outcome measures Mortality, overall and according
tothemaincausesofdeath,bythirdsofbaselinewalking
speed (measured at maximum speed over six metres),
adjusted for several potential confounders; Kaplan-Meier
survival curves by thirds of baseline walking speed. Vital
status during follow-up. Causes of death.
Results During 16414 person years of follow-up, 209
participantsdied(99fromcancer,59fromcardiovascular
disease,51fromothercauses).Participantsin thelowest
third of baseline walking speed had an increased risk of
death(hazardratio1.44,95%confidenceinterval1.03to
1.99) compared with the upper thirds. Analyses for
specific causes of death showed that participants with
lowwalkingspeedhadaboutathreefoldincreasedriskof
cardiovascular death (2.92, 1.46 to 5.84) compared with
participantswhowalkedfaster.Therewasnorelationwith
cancer mortality (1.03, 0.65 to 1.70). In stratified
analyses, cardiovascular mortality was increased across
various strata defined by sex, median age, median body
mass index (BMI), and level of physical activity.
ConclusionSlowwalkingspeedinolderpeopleisstrongly
associated with an increased risk of cardiovascular
mortality.
INTRODUCTION
There is growing interest in using walking speed in
ambulatory clinics to readily assess functional status
and motor performances in older people, and walking
speed has been recommended as a possible “vital
sign.”
1 A few studies in well functioning older people
have shown that decreased walking speed can predict
adversehealthrelatedeventssuchasfalls,
23disability,
4
admissions to hospital,
56 and “persistent lower extre-
mity limitation.”
7 Lower walking speed has also been
associated with increased all cause mortality,
8 but it is
unknown whether specific causes of death account for
this increased mortality.
As part of a prospective cohort of well functioning
older people enrolled in the Three-City (3C) study we
studiedtheprognosticvalueofwalkingspeedbyinves-
tigating its relation with mortality overall and accord-
ingtomaincausesofdeath.Becauseofrecentevidence
indicatingthatvascularriskfactorsmightbeassociated
with decreased motor performances,
910we had a spe-
cial interest in the relation between walking speed and
risk of cardiovascular death.
METHODS
The 3C study is an ongoing cohort study conducted in
three French cities (Bordeaux, Dijon, Montpellier).
Details of the study and primary outcomes have been
previouslyreported.
11Participantsaged≥65andliving
in the community were recruited from electoral rolls.
The first step of the sampling procedure was to select
administrative districts. Eligible inhabitants of the
selected districts were invited to participate by a letter
and were then contacted by phone until we reached
our target number of participants; the acceptance rate
was 37%. Data for the present study were obtained in
Dijon(n=4931), whereinvestigatorswere interestedin
motor function in older people. After baseline exami-
nation, follow-up examinations were performed at a
mean of 1.8 years (2001-2), 3.6 years (2003-4), and 5.
1 years (2005-6).
Baseline assessments
During a face-to-face interview in participants’ homes
in 1999-2001 trained psychologists collected baseline
demographic and medical data using standardised
questionnaires. Education was defined as a four level
variable(noschool/primarywithoutdiploma,primary
with diploma, secondary without a baccalaureate
degree, baccalaureate/university degree). Participants
were asked about their history of coronary artery dis-
ease (myocardial infarction, angina pectoris, coronary
revascularisation), peripheral artery disease, stroke,
Parkinson’s disease, and recent hip fracture (in the
two preceding years). Exertional dyspnoea was self
declared, based on the New York Heart Association
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twice duringthe baselineinterview, andthe averageof
these two measurements was used. Hypertension was
definedashighbloodpressure(systolicbloodpressure
≥140 mm Hg or diastolic blood pressure ≥90 mm Hg)
or use of antihypertensive medication. Participants
were considered to have diabetes if they used anti-
diabeticagentsor if theirfasting glucoseconcentration
was ≥7.0 mmol/l. Hypercholesterolaemia was defined
astotalcholesterol≥6.2mmol/loruseoflipidlowering
drugs.Smokingstatuswasclassifiedascurrent,past,or
never. Weight and height were measured and used to
calculate body mass index (BMI). Chronic use of non-
steroidal anti-inflammatory drugs (NSAIDs) for joint
pain was assessed and considered as a surrogate for
rheumatic disease. Baseline physical activity was self
reported as a three level variable assessing the daily
duration of walking and athletic activities.
DepressivesymptomswereassessedwiththeCenter
for Epidemiologic Studies Depression Scale (CES-
D).
12 Use of psychotropic drugs (anxiolytics, hypno-
tics, antidepressants) was also assessed. Participants
underwent a battery of cognitive tests, including the
mini-mental state examination (MMSE). The ability
tocompleteinstrumentalactivitiesofdailyliving(Law-
ton IADL scale) was assessed. Diagnosis of dementia
was established with a three phase procedure: partici-
pantswerescreenedusingthemini-mentalstateexam-
ination and the Isaac set test; a neurologist then
examinedthosewithpositiveresults.Thefinaldiagno-
sis was established by a panel of independent neurolo-
gists using criteria from the Diagnostic and Statistical
Manual of Mental Disorders, fourth edition.
11
Fasting blood samples were taken and glycaemia,
total cholesterol, and homocysteine concentrations
were measured at a single laboratory.
Gait assessment
After the baseline home interview, participants aged
≤85 were invited to the study centre in 1999-2001,
where we quantitatively evaluated walking speed.
Two photoelectric cells connected to a chronometer
were placedin a corridorsix metresapart.Participants
were first asked to walk at their usual speed and were
then invited to perform the maximum walking speed
test.Theywere askedtowalk downthe corridorasfast
aspossiblewithoutrunning(“Pleasewalkasquicklyas
you can without running to the end of the corridor”).
They could do one trial to check whether they under-
stood the instructions before we measured the actual
speed. In addition, participants started walking three
metres before the start line so that walking speed did
not include the acceleration time. Walking speed was
defined as the ratio between distance and time.
Outcomes
Ateachfollow-up,wecontactedparticipants;whenwe
could not reach them we contacted their relatives and
personal physicians to determine their vital status. In
case of death we obtained hospital records and infor-
mation from personal physicians. A committee
reviewed records to determine immediate and under-
lying causes of death, according to ICD-10 (inter-
national classification of diseases, 10th revision)
codes. The committee was blinded to the results of
walking speed measured once in 1999-2001.
We first considered all cause death and then defined
three subgroups: cancer, cardiovascular, other causes.
Cancermortalitywasdefinedasanimmediatecauseof
death coded by the committee between C00 and C97
and cardiovascular death as an immediate cause of
death coded between I00 and I78 (including coronary
heart disease, stroke, peripheral vascular disease, and
other cardiovascular disease) or R960 (sudden death).
Other causes of deaths included infectious diseases,
digestivecauses,trauma,suicide,anddeathofundeter-
mined cause.
Statistical analyses
We excluded from our analyses participants who had
conditions at baseline that were strongly associated
with decreased walking speed (Parkinson’s disease,
dementia, hip fracture in the previous two years, dis-
ablingstroke,coronaryarterydisease).Descriptivesta-
tistics were used to describe baseline characteristics by
vital status (deceased during follow-up, yes/no) and
thirds of walking speed. We compared groups using
Student’s t test or analysis of variance (with linear con-
trasts) forcontinuousmeasures andχ
2 testor Cochran-
Armitage trend test for proportions. Because walking
speedwasstronglyrelatedtosex,wecategoriseditinto
sex dependent thirds to maintain balanced sample
sizes in men and women (cut offs were defined by ter-
tilesofthedistributionsinmenandwomen:≤1.50m/s,
1.51-1.84m/s, and ≥1.85 m/s in men;≤1.35 m/s, 1.36-
1.50 m/s, and >1.50 m/s women).
We calculated the cumulative incidence of death
according to thirds of walking speed with the Kaplan-
Meier method and compared it with the log rank test.
Wealsocomputedthecumulativeriskofagivencause
of death taking into account other causes of death
(competing risk analysis) and found similar estimates
totheKaplan-Meieronesbecausemortalityrateswere
low,thusshowingthatcompetingrisksarenotanissue
for the present analyses. We used Cox proportional
hazard models to estimate hazard ratios for death and
their 95% confidence intervals. The proportional
hazards assumption was checked by computing
Schoenfeld residuals. We tested interactions between
variables by including interaction terms. Unadjusted
and adjusted hazard ratios are presented. Models
were initially adjusted for age and sex. We then
included in the models additional covariates strongly
associated with walking speed (education level, mini-
mentalstateexamination,BMI,height,baselinephysi-
cal activity). In the full model, we adjusted for other
covariates associated with walking speed or mortality
inunivariateanalyses(diabetesmellitus,hypertension,
use of non-steroidal anti-inflammatory drugs for joint
pain, use of psychotropic drugs, alcohol drinking,
cigarette smoking, homocysteine concentration, dysli-
pidaemia, exertional dyspnoea, peripheral artery
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sive symptoms). In sensitivity analyses, we considered
walking speed as a continuous variable or used other
cut points (quartiles, quintiles) to categorise walking
speed to assess whether our findings were influenced
by the coding of the walking speed variable. Stratified
analyseswereperformedtoassesstherelationbetween
walking speed and cardiovascular mortality in differ-
ent subgroups defined by sex, median age, median
BMI, hypertension, smoking, and physical activity
level.Insensitivityanalyses,participantswhoreported
coronaryarterydiseaseatbaselinewereretainedinthe
analyses.
All P values were twotailed, and P≤0.05 wasconsid-
ered to be significant. All statistical analyses were per-
formedwithSASversion9.1(SASInstitute,Cary,NC,
USA).
RESULTS
At baseline, 4399 participants aged 65-85 were seen at
the study centre. We excluded from the analyses 722
who had one or more prevalent medical conditions
strongly associated with decreased walking speed
(477 with coronary artery disease, 211 with stroke, 53
withParkinson’sdisease,38withdementia,12withhip
fracture). Walking speed at baseline was missing for
469 participants, who tended to be older (P<0.001)
and with a higher BMI (P<0.001) than the other parti-
cipants; there was no difference for other characteris-
tics. All cause mortality during follow-up was not
significantly higher (P=0.12) in participants without a
measure of walking speed compared with those with a
measureavailable.Themean(SD)ageofthe3208par-
ticipants included in the study was 73.2 (4.6); 2085
(65%) were women. Vital status was determined for
3200 (99.8%) and missing for 8 (0.2%) at the end of
the third follow-up (2005-6). During a mean (SD) fol-
low-up of 5.1 (1.0) years, corresponding to 16414 per-
son years, 209 participants died (99 from cancer, 59
from cardiovascular disease, 51 from other causes).
Table 1 summarises participants’ baseline charac-
teristics by vital status and thirds of walking speed.
Those who died during follow-up were older, taller,
more often men, and had a higher prevalence of
cardiovascular risk factors (diabetes mellitus, hyper-
tension, smoking) compared with survivors. About
half ofthose who diedwere in the lowestthird of walk-
ing speed, compared with one third of those who
remained alive. Those in the lowest third of walking
speed were older, smaller, had higher BMI, and were
more likely to have depressive symptoms, less educa-
tion, lower mini-mental state examination scores, and
lower physical activity levels than those in the upper
thirds of walking speed. They were also more likely to
have hypertension or diabetes, have exertional dys-
pnoea or peripheral artery disease, and die during fol-
low-up (table 1). There were no significant differences
in baseline characteristics according to causes of
mortality (data not shown), except for chronic use of
non-steroidal anti-inflammatory drugs, which was
associated with an increased cardiovascular mortality
(P=0.03).
Figure 1 shows the cumulative risk of death (all
cause, cancer, cardiovascular, other causes) by thirds
of walking speed. There was a significant difference in
all cause mortality across thirds of walking speed (log
rank, P<0.001). Kaplan-Meier curves began to sepa-
rate between 20 and 30 months after baselineand con-
tinued to diverge afterwards. The difference in the
cumulative risk of death was significant for
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Fig 1 | Kaplan-Meier estimates of cumulative incidence of death
according to thirds of walking speed, overall and by cause of
death. Cut offs (tertiles) for definition of thirds of walking
speed were ≤1.50 m/s, 1.51-1.84 m/s, and ≥1.85 m/s for men
and ≤1.35 m/s, 1.36-1.50 m/s, and >1.50 m/s for women
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death (P=0.004), while there was no significant differ-
ence for cancer deaths (P=0.26). In each of these ana-
lyses, there was no significant difference in the
cumulative incidence of death between the middle
and highest thirds of walking speed, and the increased
riskofdeathmainlyconcernedthoseinthelowestthird
of walking speed. Our subsequent results are for the
lowest third of walking speed compared with the two
upper thirds.
Table 2showsmultivariableanalysesoftherelation
between walking speed and mortality. In analyses
adjustedforageandsex(table 2,model2),participants
in the lowest third of walking speed had an increased
risk of dying during follow-up (hazard ratio 1.64, 95%
confidence interval 1.24 to 2.17) compared with those
in the upper thirds; the difference in mortality was sig-
nificantforcardiovascularmortality(2.85,1.64to4.94)
and other causes of death (1.79, 1.00 to 3.19), while
there was no association with deaths from cancer
(1.13, 0.74 to 1.71). After adjustment for other covari-
ates associated with walking speed, the association
remained significant overall and for cardiovascular
mortality (table 2, model 3). Further adjustment for
baseline vascular risk factors, psychotropic drug use,
exertional dyspnoea, peripheral artery disease, being
dependent in at least one instrumental activity of daily
living, depressive symptoms, and use of non-steroidal
anti-inflammatory drugs for joint pain led to similar
results (table 2, model 4). Inclusion of walking speed
asacontinuousvariableorusingothercutpoints(quar-
tiles or quintiles) led to similar conclusions (data not
shown).
Figure 2 shows the results of stratified analyses; in
each strata, hazard ratios are adjusted for age, sex,
BMI, height, education level, mini-mental state exam-
ination, physical activity, diabetes mellitus, hyperten-
sion, use of non-steroidal anti-inflammatory drugs for
joint pain, psychotropic drug use, alcohol, smoking,
dyslipidaemia, exertional dyspnoea, peripheral artery
disease, dependence in instrumental activities of daily
living, depressive symptoms, and homocysteine level
(model 4). In all strata, cardiovascular mortality was
higher in the lowest third of walking speed than in the
upperthirds(model4).Interactiontestscomparingthe
hazard ratios across the strata were not significant.
In analyses in which we excluded those who were
dependent in at least one instrumental activity of
daily living at baseline (171, 5.3%, table 1), the hazard
ratio (model 4) was 1.50 (1.08 to 2.08) for overall
Table 1 |Baseline characteristics of study sample by vital status and thirds of walking speed. Figures are numbers (percentages) unless stated otherwise
Characteristics
Overall
(n=3208) Missing
Died during follow-up* Thirds of walking speed†
No
(n=2991)
Yes
(n=209) P value‡
Lowest
(n=1091)
Middle
(n=1087)
Highest
(n=1030) P value§
Mean (SD) age (years) 73.2 (4.6) 0 73.1 (4.5) 75.5 (4.6) <0.001 74.9 (4.6) 73.1 (4.4) 71.6 (4.2) <0.001
Women 2070 (64.5) 0 1968 (65.8) 98 (46.9) <0.001 717 (65.7) 691 (63.6) 662 (64.3) 0.48
Mean (SD) BMI 25.6 (4.0) 2 25.6 (4.0) 25.9 (4.6) 0.22 26.6 (4.4) 25.4 (3.8) 24.8 (3.5) <0.001
Mean (SD) height (cm) 161.5 (8.64) 2 161.4 (8.6) 162.9 (8.9) 0.01 160.0 (8.5) 161.6 (8.8) 162.9 (8.4) <0.001
Low education level¶ 651 (20.3) 1 602 (20.1) 48 (23.0) 0.80 282 (25.8) 208 (19.1) 161 (15.6) <0.001
Mean (SD) MMSE score 27.5 (1.9) 4 27.5 (1.9) 27.1 (2) 0.01 27.0 (2.1) 27.6 (1.8) 27.8 (1.7) <0.001
Depressive symptoms** 390 (12.2) 29 361 (12.1) 26 (12.5) 0.89 183 (17.0) 112 (10.4) 95 (9.3) <0.001
Psychotropic drugs use 785 (24.5) 0 723 (24.2) 60 (28.7) 0.14 352 (32.3) 241 (22.2) 192 (18.6) <0.001
IADL dependent†† 171 (5.3) 23 149 (5.0) 20 (9.7) 0.004 97 (9.0) 49 (4.5) 25 (2.4) <0.001
Low physical activity‡‡ 517 (16.4) 46 476 (16.5) 41 (21.1) 0.09 228 (22.1) 156 (14.7) 133 (13.3) <0.001
Hypertension§§ 2513 (78.3) 0 2326 (77.8) 182 (87.1) 0.002 925 (84.8) 845 (77.7) 743 (72.1) <0.001
Diabetes mellitus 262 (8.2) 0 224 (7.5) 38 (18.2) <0.001 113 (10.4) 82 (7.5) 67 (6.5) 0.001
Hypercholesterolaemia¶¶ 1856 (57.9) 1 1741 (58.2) 112 (53.9) 0.22 633 (58.1) 623 (57.3) 600 (58.3) 0.90
Mean (SD) homocysteine (µmol/l) 14.7 (5.2) 103 14.6 (5.2) 15.0 (4.89) 0.30 15.4 (5.7) 14.6 (5.1) 14.0 (4.5) <0.001
Former or current smokers 1175 (36.6) 0 1072 (35.8) 99 (47.4) 0.01 381 (34.9) 396 (36.4) 398 (38.6) 0.48
Current drinker 2532 (78.9) 8 2362 (79.2) 164 (78.5) 0.81 855 (78.4) 849 (78.2) 828 (80.7) 0.24
Peripheral artery disease 76 (2.4) 43 61 (2.0) 14 (6.7) <0.001 40 (3.7) 17 (1.6) 19 (1.9) 0.005
Exertional dyspnoea 381 (11.9) 7 334 (11.2) 45 (21.6) <0.001 199 (18.3) 109 (10.0) 73 (7.1) <0.001
NSAIDs for joint pain 474 (14.8) 37 443 (15.0) 30 (14.6) 0.87 216 (20.1) 152 (14.2) 106 (10.4) <0.001
Walking speed in lower third 1091 (34.0) 0 982 (32.8) 105 (50.2) <0.001 —— — —
Died during follow-up 209 (6.5) 8 —— — 105 (9.7) 49 (4.5) 55 (5.4) <0.001
BMI=body mass index; MMSE=mini-mental state examination, IADL=instrumental activity of daily living; NSAID=non-steroidal anti-inflammatory drug.
*Vital status not determined for eight people.
†Cut offs (tertiles): ≤1.50 m/s, 1.50-1.85 m/s, and ≥1.85 m/s for men and ≤1.35 m/s, 1.35-1.50 m/s, and >1.50 m/s for women.
‡χ
2 test for proportions and Student’s t test for continuous measures.
§Cochran-Armitage trend test for proportions and analysis of variance (linear contrasts) for continuous measures.
¶No school or primary school without diploma.
**Assessed by Center of Epidemiological Studies Depression Scale.
††Dependent for at least one activity of the Lawton IADL scale.
‡‡Defined as walking less than 1 hour/day and no sport activity.
§§Systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg or intake of antihypertensive drugs.
¶¶Total cholesterol concentration ≥6.20 mmol/l or intake of lipid lowering drugs.
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mortality, while there was no association with other
causes of death (1.21, 0.62 to 2.38) and cancer mortal-
ity (1.10, 0.68 to 1.79). In sensitivity analyses, we
included participants who reported coronary artery
disease at baseline and had a measurement of walking
speed; our findings remained unchanged. Hazard
ratios (model 4) were 1.41 (1.05 to 1.89) for overall
mortality, 2.48 (1.33 to 4.62) for cardiovascular mor-
tality,1.11 (0.72 to 1.72)for cancer mortality,and 1.34
(0.77 to 2.32) for other causes of death.
DISCUSSION
In this large cohort of older people living in the com-
munity we found that lower walking speed at baseline
was associated with increased mortality during a five
yearfollow-up.Participantsinthelowestthirdofwalk-
ing speed had a 44% increased risk of death compared
with those in the upper thirds. With regard to specific
causesofdeath,participantsinthelowestthirdofwalk-
ing speed had about a threefold increased risk of
cardiovascular death, while no relation was found
with cancer mortality. This increased risk of cardio-
vascular death was seen in both sexes, younger as
well as in older participants, those with or without a
high risk vascular profile, and those with low or usual
physical activity.
Findings in context and possible mechanisms
Few studies have investigated the relation between
walking speed and mortality, and their methods were
not uniform.
13 One study found that regular walking
speed below 1 m/s was associated with mortality in
older people,
7 and another study found that a measure
of walking speed alone provided information on mor-
tality similar to that provided by a more complex eva-
luation of physical performance.
8 It was unknown,
however, whether specific causes of death accounted
for this increased mortality. Our results show that the
increased mortality observed in slow walkers was
mostly cardiovascular mortality. Other causes of
deathtendedtobehigherinpeoplewithlowerwalking
speed, but the relatively low number of events did not
allow detailed analyses. Additionally, after adjustment
for covariates associated with walking speed or death,
the association between walking speed and other
causes of death was considerably attenuated. Stratified
analysesshowedthattheexcesscardiovascularmortal-
ity among people who walked more slowly was
observed in different subgroups.The relationbetween
walking speed and mortality was not explained by
inclusion of participants who were dependent in at
least one instrumental activity of daily living at
Table 2 |Relation between walking speed and risk of death, overall and from specific causes
Cause of death and
walking speed
Person
years Events
Rate
(‰)
Hazard ratio (95% CI), P value
Model 1* Model 2† Model 3‡ Model 4§
All causes
Upper thirds¶ 10 940 104 9.5 1.00 1.00 1.00 1.00
Lower third** 5474 105 19.2 2.07 (1.58 to 2.72), <0.001 1.64 (1.24 to 2.17), <0.001 1.58 (1.16 to 2.15), 0.002 1.44 (1.03 to 1.99), 0.02
Cancer
Upper thirds¶ 10 940 59 5.4 1.00 1.00 1.00 1.00
Lower third** 5474 40 7.3 1.38 (0.93 to 2.07), 0.11 1.13 (0.74 to 1.71), 0.56 1.04 (0.66 to 1.60), 0.83 1.03 (0.65 to 1.70), 0.83
Cardiovascular disease
Upper thirds¶ 10 940 21 1.9 1.00 1.00 1.00 1.00
Lower third** 5474 38 6.9 3.66 (2.18 to 6.13), <0.001 2.85 (1.64 to 4.94), <0.001 3.00 (1.65 to 5.47), <0.001 2.92 (1.46 to 5.84), 0.002
Other causes
Upper thirds¶ 10 940 24 2.2 1.00 1.00 1.00 1.00
Lower third** 5474 27 4.9 2.32 (1.38 to 3.88), 0.001 1.79 (1.00 to 3.19), 0.05 1.80 (0.96 to 3.35), 0.06 1.41 (0.74 to 2.67), 0.30
*Unadjusted model.
†Adjusted for age and sex.
‡Adjusted for variables included in previous model plus body mass index (BMI), height, education level, mini-mental state examination, and physical activity.
§Adjusted for variables included in previous model plus diabetes mellitus, hypertension, use of non-steroidal anti-inflammatory drugs for joint pain, psychotropic drug use, alcohol, smoking,
dyslipidaemia, exertional dyspnoea, peripheral artery disease, dependence for at least one instrumental activity of daily living, depressive symptoms, and homocysteine concentration.
¶Reference.
**Cut off for walking speed: ≤1.50 m/s for men and ≤1.35 m/s for women.
Men
Women
Age ≤73
Age >73
BMI ≤25.2
BMI >25.2
No hypertension
Hypertension
Never smokers
Former and current smokers
Low physical activity
Usual physical activity
2.45 (1.08 to 5.10)
3.57 (1.17 to 10.84)
3.47 (1.03 to 11.71)
2.61 (1.23 to 5.54)
2.51 (1.00 to 6.39)
3.66 (1.43 to 9.33)
4.88 (1.18 to 20.29)
2.48 (1.19 to 5.18)
2.39 (1.05 to 5.46)
4.87 (1.66 to 14.30)
4.08 (0.83 to 20.08)
2.84 (1.37 to 5.85)
36
23
19
40
28
31
16
43
35
24
13
40
0.5 5 2 12 0
Subgroup Hazard ratio
(95% CI)
Hazard ratio
(95% CI)
No who
died
Fig 2 | Walking speed in lowest third and risk of cardiovascular death: stratified analyses.
Hazard ratios estimate relative risk of cardiovascular death in those in lowest third of walking
speed (≤1.50 m/s for men; ≤1.35 m/s for women) compared with those in two highest thirds
(reference group)
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lyses restricted to non-dependent participants were
comparable with the overall analyses.
In a previous study, performance of long distance
walking in a corridor was associated with cardio-
vascular events.
14 Measures of walking speed over a
short distance and long distance corridor walking
tests are not readily comparable. Long distance walk-
ing tests measure features such as endurance, fatigabil-
ity, and cardiovascular fitness that are not assessed
through short distance measures of walking speed.
15
Ourresultsarealsoinlinewithpreviousstudiesreport-
ing an association between increased cardiovascular
mortality and low cardiorespiratory fitness
16 or low
physical activity.
17 Measures of walking speed over a
distance of six metres are easier to implement in rou-
tine clinical practice and represent objective measures
thatcanbeassessedrepeatedly;theycanbeperformed
in a few seconds in nearly all older people living in the
community, while tests of long distance walking
requirearoundeightminutesandcannotbeperformed
by a sizeable proportion of older people.
A possible explanation for the association between
low walking speed and cardiovascular mortality is that
chronic exposure to vascular risk factors is associated
with both increased cardiovascular mortality and
decreased walking speed. Until recently, the relation
between vascular risk factors and motor performances
received little attention, but there is some evidence in
favourofanassociation.Increasedthicknessofthecar-
otid artery intima media
10 and raised homocysteine
concentrations
18 have been reported to be associated
withlowwalkingspeed,whileraisedhighdensitylipo-
proteincholesterolconcentrationshave been reported
to be associated with higher walking speed.
19 Recent
studies have shown an association between perfor-
mance measures and inflammatory markers,
20 and
inflammation is suspected to play a role in cardio-
vascular disease.
21 Diabetes mellitus has been asso-
ciated with symptoms of mild parkinsonism in older
people,
22 suggesting the involvement of deep cerebral
lesions. These associations might be mediated by sub-
clinical cerebrovascular disease in patients with vascu-
lar risk factors.
23-27
Alternative explanations are possible. Low walking
speed might result from the peripheral effect of vascu-
lar risk factors—for example, heart failure or periph-
eral artery disease.
28 Adjustment for these conditions,
however, did not modify the association between
lower walking speed and cardiovascular mortality.
We should also consider that low physical activity,
which was associated with decreased walking speed,
might increase the prevalence of vascular risk factors
such as hypertension
29 or diabetes mellitus.
30 How-
ever, the association remained after adjustment for,
or stratification by, level of physical activity.
Strengths and limitations
The low proportion of participants who were lost to
follow-up (eight out of 3208) is one of the main
strengths of this study. Other strengths include the
large number of person years and an automated mea-
sure of walking speed using photoelectric cells, which
ensures high reproducibility of the measure.
Therearelimitationstoconsider.The3Ccohortwas
volunteer based and not representative of the general
population. Participants were community dwelling,
well functioning older people who were able to come
by themselves to the study centre. Although this is
likely to lead to an underestimation of the incidence
of events such as death, it has been shown that, in this
setting, the relation between baseline exposure and
incidence of disease during follow-up is not biased.
31
Increased cardiovascular mortality was present only
for participants in the lowest third of walking speed,
suggesting a threshold effect. The number of cardio-
vascular deaths, however, did not allow us to deter-
mine a more precise cut off.
Conclusion
In summary, lower walking speed was strongly asso-
ciated with cardiovascular mortality in a population
of well functioning older people. These findings show
thatassessmentofmotorperformancesinolderpeople
with simple measures such as walking speed can be
performed easily and that the role of fitness in preser-
ving life and function in older age is important.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Walking speed is a simple and reliable measure that is considered as a surrogate for overall
quality of gait and motor function in older people
Decreased walking speed has been shown to be associated with several adverse health
related events, including death
WHAT THIS STUDY ADDS
Participants with a walking speed in the lower third of the distribution had about a threefold
increasedriskofcardiovasculardeath,but noincreasedriskofmortality fromcancer orother
causes of death
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